Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Duos Technologies Group joins Webull Corporate Communications platform » 08:27
02/02/23
02/02
08:27
02/02/23
08:27
DUOT

Duos Technologies Group

$4.53 /

-0.07 (-1.52%)

Duos Technologies Group…

Duos Technologies Group announced that the Company is one of approximately 35 Nasdaq-listed firms to be participating on the new Webull Corporate Communications Service Platform. The Duos Technologies portal on the Webull Platform will help provide the Company with a direct line of communication to shareholders and followers by providing instant notifications regarding corporate content such as company news, earnings reports, investor presentations, and more.

ShowHide Related Items >><<
DUOT Duos Technologies Group
$4.53 /

-0.07 (-1.52%)

DUOT Duos Technologies Group
$4.53 /

-0.07 (-1.52%)

01/18/23 Ascendiant
Duos Technologies Group initiated with a Buy at Ascendiant
06/17/22
Duos Technologies Group management to meet virtually with Northland
03/03/22 Northland
Duos Technologies Group initiated with an Outperform at Northland
DUOT Duos Technologies Group
$4.53 /

-0.07 (-1.52%)

  • 04
    Feb
DUOT Duos Technologies Group
$4.53 /

-0.07 (-1.52%)

Wednesday
Hot Stocks
Pressure BioSciences receives $600,000 order for 16 PCT instruments » 09:49
02/01/23
02/01
09:49
02/01/23
09:49
PBIO

Pressure BioSciences

$1.95 /

-0.105 (-5.11%)

Pressure BioSciences…

Pressure BioSciences announced entrance into an exclusive distribution agreement for the People's Republic of China with PRS International Trade. PRS International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly $600,000, with a commitment to purchase additional units and related consumables before the end of 2023. This historic purchase of PBIO's original high-pressure technology instruments comes on the back of a surge in purchase orders for all product categories of the Company's pressure-based instruments and consumables.

ShowHide Related Items >><<
PBIO Pressure BioSciences
$1.95 /

-0.105 (-5.11%)

PBIO Pressure BioSciences
$1.95 /

-0.105 (-5.11%)

Downgrade
VolitionRx downgraded to Hold at Benchmark on valuation » 07:41
02/01/23
02/01
07:41
02/01/23
07:41
VNRX

VolitionRx

$2.49 /

-0.105 (-4.05%)

Benchmark analyst Bruce…

Benchmark analyst Bruce Jackson downgraded VolitionRx to Hold from Buy with no price target. VolitionRx announced a "string of positive news" for its Nu.Q vet business and continues to move forward with development of its human test for netosis, but even if the firm were to assume 2025 revenue north of $50M, a price target of $2.90 it would derive from that "would represent modest upside to the current price considering the duration risk," prompting it to lower its rating based on the stock's current valuation.

ShowHide Related Items >><<
VNRX VolitionRx
$2.49 /

-0.105 (-4.05%)

VNRX VolitionRx
$2.49 /

-0.105 (-4.05%)

02/01/23 Benchmark
VolitionRx downgraded to Hold from Buy at Benchmark
12/19/22 EF Hutton
VolitionRx initiated with a Buy at EF Hutton
08/23/22 Maxim
VolitionRx price target lowered to $5 from $8 at Maxim
02/17/22 Cantor Fitzgerald
VolitionRx assumed with an Overweight at Cantor Fitzgerald
  • 29
    Jul
Downgrade
VolitionRx downgraded to Hold from Buy at Benchmark » 06:48
02/01/23
02/01
06:48
02/01/23
06:48
VNRX

VolitionRx

/

+

Benchmark analyst Bruce…

Benchmark analyst Bruce Jackson downgraded VolitionRx to Hold from Buy.

ShowHide Related Items >><<
VNRX VolitionRx
/

+

VNRX VolitionRx
/

+

12/19/22 EF Hutton
VolitionRx initiated with a Buy at EF Hutton
08/23/22 Maxim
VolitionRx price target lowered to $5 from $8 at Maxim
02/17/22 Cantor Fitzgerald
VolitionRx assumed with an Overweight at Cantor Fitzgerald
  • 29
    Jul
Monday
Initiation
Onfolio initiated with a Buy at EF Hutton » 16:17
01/30/23
01/30
16:17
01/30/23
16:17
ONFO

Onfolio

$1.97 /

+0.15 (+8.24%)

EF Hutton analyst Michael…

EF Hutton analyst Michael Albanese initiated coverage of Onfolio with a Buy rating and $3 price target. The analyst says Onfolio is an "under-the-radar, diversified portfolio of highly cash-generative online businesses that is currently trading below its net cash position."

ShowHide Related Items >><<
ONFO Onfolio
$1.97 /

+0.15 (+8.24%)

  • 26
    Aug
ONFO Onfolio
$1.97 /

+0.15 (+8.24%)

Hot Stocks
ACCESSWIRE acquires Newswire, terms not disclosed » 09:14
01/30/23
01/30
09:14
01/30/23
09:14
ISDR

Issuer Direct

$26.40 /

+0.17 (+0.65%)

ACCESSWIRE acquired…

ACCESSWIRE acquired Newswire, an industry leader in press release distribution services and media technology in November 2022. This integration blends the unique assets of each brand to provide a comprehensive host of services that help companies of all sizes and industries, public and private, effectively deliver their stories to maximize the moment.

ShowHide Related Items >><<
ISDR Issuer Direct
$26.40 /

+0.17 (+0.65%)

Over a week ago
Syndicate
Nemaura Medical prices $8.4M registered direct offering » 08:22
01/27/23
01/27
08:22
01/27/23
08:22
NMRD

Nemaura Medical

$2.85 /

+0.215 (+8.17%)

Nemaura Medical announced…

Nemaura Medical announced it has entered into a definitive agreement with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock, pursuant to a registered direct offering, and warrants to purchase up to 4,796,206 Shares, in a concurrent private placement. The combined purchase price for one Share and one Warrant will be $1.75. The Warrants will have an exercise price of $2.00 per Share, will be initially exercisable at the later of shareholder approval or 6 months following the date of issuance and will expire five and a half years from the closing date. The aggregate gross proceeds from the Registered Direct Offering and the concurrent Private Placement are expected to be approximately $8.4 million before deducting placement agent fees and other estimated offering expenses. EF Hutton, division of Benchmark Investments, LLC, is acting as sole placement agent for the offering.

ShowHide Related Items >><<
NMRD Nemaura Medical
$2.85 /

+0.215 (+8.17%)

NMRD Nemaura Medical
$2.85 /

+0.215 (+8.17%)

08/19/22 H.C. Wainwright
Nemaura Medical price target lowered to $8 from $12 at H.C. Wainwright
03/29/22 H.C. Wainwright
Nemaura Medical initiated with a Buy at H.C. Wainwright
NMRD Nemaura Medical
$2.85 /

+0.215 (+8.17%)

Hot Stocks
Pressure BioSciences, One World Pharma partner for sports drink development » 08:19
01/27/23
01/27
08:19
01/27/23
08:19
PBIO

Pressure BioSciences

$2.14 /

+0.02 (+0.94%)

Pressure BioSciences and…

Pressure BioSciences and One World Products announced they have entered into an active collaboration agreement under which the two companies will combine their strong, symbiotic capabilities to develop an innovative line of next generation sports performance/recovery drinks.

ShowHide Related Items >><<
PBIO Pressure BioSciences
$2.14 /

+0.02 (+0.94%)

PBIO Pressure BioSciences
$2.14 /

+0.02 (+0.94%)

Hot Stocks
Nemaura Medical receives first purchase order from HealthFleet » 09:58
01/26/23
01/26
09:58
01/26/23
09:58
NMRD

Nemaura Medical

$3.27 /

+0.64 (+24.33%)

Nemaura Medical announced…

Nemaura Medical announced receipt of a first purchase order for 5,000 proBEAT subscriptions from HealthFleet, a telehealth provider focusing on care, coaching, and health recommendations. The purchase order consists of 75,000 proBEAT glucose sensors over an initial five month period and is valued at $500,000 in revenue. HealthFleet has an option to increase volumes based on customer response.

ShowHide Related Items >><<
NMRD Nemaura Medical
$3.27 /

+0.64 (+24.33%)

NMRD Nemaura Medical
$3.27 /

+0.64 (+24.33%)

08/19/22 H.C. Wainwright
Nemaura Medical price target lowered to $8 from $12 at H.C. Wainwright
03/29/22 H.C. Wainwright
Nemaura Medical initiated with a Buy at H.C. Wainwright
NMRD Nemaura Medical
$3.27 /

+0.64 (+24.33%)

Hot Stocks
Nemaura Medical receives first purchase order from HealthFleet » 08:11
01/26/23
01/26
08:11
01/26/23
08:11
NMRD

Nemaura Medical

$2.63 /

-0.12 (-4.36%)

Nemaura Medical announced…

Nemaura Medical announced receipt of an initial purchase order for 5,000 proBEAT subscriptions from HealthFleet, a leading telehealth provider focusing on care, coaching, and health recommendations. The purchase order consists of 75,000 proBEAT glucose sensors over an initial five month period and is valued at $500,000 in revenue. HealthFleet has an option to increase volumes based on customer response. Dr. Faz Chowdhury, Nemaura's Chief Executive Officer, stated, "The HealthFleet purchase order is our first collaboration in the United States and provides an important opportunity to potentially improve outcomes for people with type 2 diabetes by integrating our proBEAT platform into HealthFleet's RestoreHealth program. We are confident that our proprietary sensor technology can improve patient engagement and potential outcomes in the RestoreHealth program and believe that the potential improved outcomes in this pilot can help to position this as the program of choice across the U.S. health economy."

ShowHide Related Items >><<
NMRD Nemaura Medical
$2.63 /

-0.12 (-4.36%)

NMRD Nemaura Medical
$2.63 /

-0.12 (-4.36%)

08/19/22 H.C. Wainwright
Nemaura Medical price target lowered to $8 from $12 at H.C. Wainwright
03/29/22 H.C. Wainwright
Nemaura Medical initiated with a Buy at H.C. Wainwright
NMRD Nemaura Medical
$2.63 /

-0.12 (-4.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.